CXCL13, an inflammatory biomarker, may be a good marker of likely future disease activity in people with multiple sclerosis (MS), a study suggests.
The study, “Intrathecally produced CXCL13: A predictive biomarker in multiple sclerosis,” was published in the Multiple Sclerosis Journal – Experimental, Translational and Clinical.
Clinicians caring for people with MS need better molecular biomarkers to aid them in identifying patients at risk of disease progression and to help in its management.
CXCL13 — a known marker of inflammation — has been suggested as a potential prognostic biomarker for MS, as its levels are extremely high in patients.
Researchers at the Dartmouth Hitchcock Medical Center, in New Hampshire, examined the predictive value of CXCL13 in determining future disease activity in these people.
CXCL13 was compared to other biomarkers, namely: oligoclonal bands (OCBs), a measure of antibodies in the central nervous system, which is broadly indicative of inflammation; and neurofilament light (NfL), a biomarker of neuronal damage.
The study included 67 MS patients (mean age, 41.8) and 67 matched controls (mean age, 45) with non-inflammatory neurologic disease. Five patients with a follow-up of less than six months were excluded from the analyses; others were followed for about 2.5 years.
Patients presented different types of MS: 41 had clinically isolated syndrome (CIS), 13 had primary progressive MS (PPMS), eight had relapsing-remitting MS (RRMS), four had radiologically isolated syndrome (RIS), and one person had secondary progressive MS (SPMS).
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?